Drugs Made In America Acquisition LLC
CIK 2038492 · View on SEC EDGAR ↗
First SEC filing: Jan. 10, 2025 · Latest: March 3, 2025
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 18, 2025 | DMAAR | P | 30,000 | — | — | 430,000 Direct | +7.50% | Acquired | (price as of 2026-08-21) |
| Feb. 18, 2025 | DMAAR | P | 30,000 | — | — | 4,188,780 Direct | +0.72% | Acquired | (price as of 2026-08-21) |
| Jan. 29, 2025 | DMAAR | P | 400,000 | — | — | 400,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Jan. 29, 2025 | DMAAR | S | 5,698,363 | — | — | 4,158,780 Direct | -57.81% | Disposed | (price as of 2026-08-21) |
| Jan. 29, 2025 | DMAAR | P | 400,000 | — | — | 10,257,143 Direct | +4.06% | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 18, 2025 | DMAAR | Rights to receive ordinary shares | Ordinary shares (30,000) | — | — | 30,000 | Acquired |
| Jan. 29, 2025 | DMAAR | Rights to receive ordinary shares | Ordinary shares (400,000) | — | — | 400,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Jan. 10, 2025 | DMAAR | Ordinary Shares | 9,857,143 | Direct |